3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
1
Status
Terminated
2
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
3
Myeloid
3
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
21
Leukemia
9
Gastrointestinal Stromal Tumors
4
Philadelphia Chromosome
3
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid
3
Bone Marrow Diseases
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Myeloproliferative Disorders
2
Hematologic Neoplasms
2
Bronchiolitis Obliterans Syndrome
2
Sarcoma
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Hematologic Diseases
1
Interventions
Imatinib Mesylate
5
nilotinib
3
ponatinib
2
thymoglobulin
1
enasidenib
1
bosutinib
1
Transplantation
1
Standard of Care
1
Mycophenolic Acid
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone Acetate
1
Methylprednisolone
1
Hematopoietic Stem Cell Transplantation
1
Cytarabine
1
Cyclosporine
1
BID protein, human
1
Azacitidine
1
Antilymphocyte Serum
1
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Myeloid
×
nilotinib
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts
NCT00471497
2020-11-18
ENESTnd
Novartis
Phase 3
Completed
846 enrolled
33 charts
NCT00519090
2011-11-07
ENEST
Novartis
Phase 3
Terminated
6 enrolled
6 charts